In light of GPR55’s role in promoting inflammation in various experimental models, such as colitis, non-alcoholic steatohepatitis, atherosclerosis, and asthma associated with obesity [1,2,9,20,21,23], this research explores the potential of inhibiting GPR55 for treating autoimmune diseases affecting the joints. The gene discussed is GPR55; the disease is metabolic dysfunction-associated steatohepatitis.